Keros Therapeutics (NASDAQ:KROS) Announces Earnings Results, Misses Expectations By $0.02 EPS

Posted by Scott Moore on Aug 10th, 2024

Keros Therapeutics (NASDAQ:KROS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02), Briefing.com reports. The company had revenue of $0.04 million for the quarter. During the same period last year, the business earned ($1.27) EPS.

Keros Therapeutics Stock Up 2.2 %

Shares of Keros Therapeutics stock traded up $0.97 on Friday, hitting $45.38. 156,072 shares of the company’s stock traded hands, compared to its average volume of 379,742. The firm’s 50-day moving average is $47.26 and its 200 day moving average is $55.12. The stock has a market cap of $1.64 billion, a P/E ratio of -8.81 and a beta of 1.23. Keros Therapeutics has a 52-week low of $27.02 and a 52-week high of $73.00.

Analysts Set New Price Targets

A number of equities analysts have recently commented on KROS shares. Oppenheimer began coverage on shares of Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $92.17.

Check Out Our Latest Stock Report on KROS

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.